A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Title:
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Author:
Veeraraghavan, J. De Angelis, C. Mao, R. Wang, T. Herrera, S. Pavlick, A.C. Contreras, A. Nuciforo, P. Mayer, I.A. Forero, A. Nanda, R. Goetz, M.P. Chang, J.C. Wolff, A.C. Krop, I.E. Fuqua, S.A.W. Prat, A. Hilsenbeck, S.G. Weigelt, B. Reis-Filho, J.S. Gutierrez, C. Osborne, C.K. Rimawi, M.F. Schiff, R.